Human Influenza A/PR/8/34 (H1N1) Purified Virus
Catalog #: 10-210-500
Size: 0.5 mg
In Stock
Biological Substance B
Human Influenza A/PR/8/34 (H1N1) virus purified from infected chicken embryo allantoic fluid.
≥ 5 x 1010 viral particles per mL of purified Human Influenza A/PR/8/34 (H1N1)
≥ 108.0 TCID50 per mL of purified Human Influenza A/PR/8/34 (H1N1)
Typical lot size 100-500 vials
For research use only.
APPLICATION FOR USE
- In vitro Infectivity Assay
- Hemagglutination Assay (HA)
- Antiviral Studies
- Animal Experimentation
- Nucleic Acid Extraction
- Spiking Studies
- Hemagglutination Inhibition Assay (HAI)
- Virus Neutralization Assay
- Virus Ultrastructural Studies
QUALITY CONTROL TESTING INCLUDES
- Sterility
- TCID50
- Hemagglutination Assay
- Protein Concentration
- Virus Particle Count
SHIPPING AND STORAGE:
This product is shipped frozen on dry ice. Store at -70°C upon receipt. Avoid multiple freeze-thaw cycles as product degradation may result.
RECOMMENDATIONS:
Upon thawing, centrifuge the vial for a few seconds to remove residual droplets from the lid.
SAFE HANDLING RECOMMENDATIONS:
This preparation of Influenza virus is a BIOHAZARDOUS material containing ACTIVE VIRUS and should be handled in accordance with biosafety guidelines defined in the BMBL, NIH-CDC HHS Publication No. (CDC) 21-1112.
REFERENCE ARTICLES
Roosenhoff, R., Reed, V., Kenwright, A., Schutten, M., Boucher, C., Monto, A., Clinch, B., Kumar, D., Whitley, R., and Nguyen-Van-Tam, J. et al. (2019). Viral Kinetics and Resistance Development in Children Treated with Neuraminidase Inhibitors: The Influenza Resistance Information Study (IRIS). Clinical Infectious Diseases, ciz939. https://doi.org/10.1093/cid/ciz939
Roosenhoff, R., van der Vries, E., van der Linden, A., van Amerongen, G., Stittelaar, K., Smits, S., Schutten, M., and Fouchier, R. (2018). Influenza A/H3N2 virus infection in immunocompromised ferrets and emergence of antiviral resistance. PLOS ONE 13, e0200849. https://doi.org/10.1371/journal.pone.0200849
Barauskas, O., Xing, W., Aguayo, E., Willkom, M., Sapre, A., Clarke, M., Birkus, G., Schultz, B., Sakowicz, R., and Kwon, H. et al. (2017). Biochemical characterization of recombinant influenza A polymerase heterotrimer complex: Polymerase activity and mechanisms of action of nucleotide analogs. PLOS ONE 12, e0185998. https://doi.org/10.1371/journal.pone.0185998
Jaligama, S., Saravia, J., You, D., Yadav, N., Lee, G., Shrestha, B., and Cormier, S. (2017). Regulatory T cells and IL10 suppress pulmonary host defense during early-life exposure to radical containing combustion derived ultrafine particulate matter. Respiratory Research 18:15. https://doi.org/10.1186/s12931-016-0487-4
Naikawadi, R., Disayabutr, S., Mallavia, B., Donne, M., Green, G., La, J., Rock, J., Looney, M., and Wolters, P. (2016). Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis. JCI Insight 1, e86704. https://doi.org/10.1172/jci.insight.86704
Lee, G., Saravia, J., You, D., Shrestha, B., Jaligama, S., Hebert, V., Dugas, T., and Cormier, S. (2014). Exposure to combustion generated environmentally persistent free radicals enhances severity of influenza virus infection. Particle And Fibre Toxicology 11:57. https://doi.org/10.1186/s12989-014-0057-1
-
10-259-000Human Influenza A/2/Japan/305/57 (H2N2) Purified Virus1.0 mg
Biohazard Category B
-
10-280-500Human Influenza A/California/4/2009 (H1N1) Purified Virus (Swine-Origin)0.5 mg
Biohazard Category B
-
10-285-500Human Influenza A/California/4/2009 (H1N1) Purified Virus (Swine-Origin), UV-Inactivated0.5 mg
-
10-201-500Human Influenza A/Hong Kong/8/68 (H3N2) Purified Virus0.5 mg
Biohazard Category B
-
10-281-500Human Influenza A/Mexico/4108/2009 (H1N1) Purified Virus (Swine-Origin)0.5 mg
Biohazard Category B
-
10-273-500Human Influenza A/PR/8/34 (H1N1) Purified Virus, UV-Inactivated0.5 mg$12,700
-
10-267-500Human Influenza A/PR/8/34 (H1N1) Purified Virus, ß-PL Inactivated0.5 mg
-
10-220-500Human Influenza B/Lee/40 Purified Virus0.5 mg
Biohazard Category B
